



File #1625

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bernd RIEDL et al.

Confirmation No.: 6634

Serial No.: 10/042,203

Examiner: Rita J. Desai

Filed: January 11, 2002

Group Art Unit: 1625

Title: **ω-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS**

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.56, 1.97 AND 1.98**

United States Patent and Trademark Office  
Customer Service Window  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

**TIMING AND FEES**

- Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:
  - within three months of the filing date of a national application other than a CPA under § 1.53(d);
  - within three months of the actual filing date of the national phase of a PCT application; OR
  - before the mailing of a first substantive office action (including after filing of an RCE).
- Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:
  - a final rejection under 37 C.F.R. § 1.113;
  - termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P. § 609(B)(2); OR
  - a notice of allowance under 37 C.F.R. § 1.311; and

is accompanied by:

10/31/2005 SZEWDIE1 00000059 10042203

01 FC:1806

180.00 OP

- the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
  - a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
- Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:
- a final action under 37 C.F.R. § 1.113;
  - termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P. § 609(B)(2); OR
  - a notice of allowance under 37 C.F.R. § 1.311;
- AND is filed on or before payment of the issue fee; AND is accompanied by:
- the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).

#### **STATEMENTS UNDER 37 C.F.R. 1.97(e)**

- Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.

#### **CITED MATERIALS**

- Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No. \_\_\_\_\_, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).
- Copies of materials listed but not attached were cited in an international search report dated \_\_\_\_\_.
- Not required by 37 CFR § 1.98.
- Copies of the materials listed are attached (except for the foregoing).

#### **NON-ENGLISH LANGUAGE REFERENCES**

- An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
- A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:

X = document of particular relevance when it is taken alone  
Y = document of particular relevance when it is combined with another such document  
A = document defining the general state of the art  
O = non-written disclosure  
P = intercalated document  
T = document cited to understand the theory or principle underlying the invention  
E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date  
D = cited in the application  
L = cited for another reason  
& = publication of member of same patent family


Translation of other relevant information on foreign search report

**OTHER INFORMATION**

None

**PAYMENT OF FEES DUE (IF ANY):**

- A check for \$180.00 covering the fee identified above is attached.  
 Please charge to Deposit Account No. 13-3402 \$ \_\_\_\_\_ for the fee identified above.  
 The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account No. 13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,  


Richard J. Traverso, Reg. No. 30,595  
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO &  
BRANIGAN, P.C.  
Arlington Courthouse Plaza 1, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: BAYER-25A

Date: October 28, 2005

(RJT/sm) K:\BAYER\25A\03 8 1400 (2).doc

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

OCT 28 2005

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

9

**Complete if Known**

Application Number	10/042,203
Filing Date	January 11, 2002
First Named Inventor	Bernd RIEDL et al.
Group Art Unit	1625
Examiner Name	Rita J. Desai
Attorney Docket Number	BAYER-25A

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
A1	2002/017507	A1	Santora et al.		11-21-2002
A2	2002/0065283	A1	McMahon et al.		05-30-2002
A3	2002/0065296	A1	Dumas et al.		05-30-2002
A4	2004/0209905	A1	Kubo et al.		10-21-2004
A5	5063247		Sekiya et al.		11-05-1991
A6	5151344		Abe et al.		09-29-1992
A7	5658903		Adams et al.		08-19-1997
A8	5710094		Minami et al.		01-20-1998
A9	5559137		Adams et al.		09-24-1996
A10	5808080		Bell et al.		09-15-1998
A11	6297381	B1	Cirillo et al.		10-02-2001
A12	6310068	B1	Böttcher et al.		10-30-2001
A13	6329415	B1	Cirillo et al.		12-11-2001
A14	6358945	B1	Breitfelder et al.		03-19-2002
A15	6372773	B1	Regan		04-16-2002
A16	6492393	B1	Breitfelder et al.		12-10-2002
A17	6525046	B1	Cirillo et al.		02-25-2003
A18	6583282	B1	Zhang et al.		06-24-2003
A19	6608052	B2	Breitfelder et al.		08-19-2003

FOREIGN PATENT DOCUMENTS					
Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
B1	WO	02/14311	A2	Amgen Inc.	02-21-2002
B2	WO	02/32872	A1	Eisai Co. Ltd.	04-25-2002
B3	WO	02/44158	A1	Pfizer Products Inc.	06-06-2002
B4	WO	02/07772	A2	Boehringer Ingelheim	01-31-2002
B5	WO	02/32872	A1	Eisai Co. Ltd.	04-25-2002
B6	WO	01/04115	A2	Boehringer Ingelheim	01-18-2001
B7	WO	99/62890	A1	Pfizer Products Inc.	12-09-1999

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box →

OCT 28 2005  
PTO/SB/08A (08-00)  
PATENT & TRADEMARK OFFICE  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Approved for use through 10/31/2002. OMB 0651-0031  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

9

Complete if Known

Application Number	10/042,203
Filing Date	January 11, 2002
First Named Inventor	Bernd RIEDL et al.
Group Art Unit	1625
Examiner Name	Rita J. Desai

Attorney Docket Number

BAYER-25A

### FOREIGN PATENT DOCUMENTS (cont'd)

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
B8	JP	01200254	A2	Hirabayashi Shigeto	08-11-1989			
B9	JP	01102461	A2	Hirabayashi Shigeto	04-20-1989			
B10	JP	01259360	A2	Hirabayashi Shigeto	10-17-1989			
B11	JP	01009455	A2	Megumi et al.	01-12-1989			
B12	JP	06075172	B4	Megumi et al.	09-07-1988			
B13	JP	06120039	A2	Hideki	10-02-1992			
B14	JP	03144634	A2	Shigeto et al.	06-20-1991			
B15	JP	03198049	A2	Jiro et al.	12-27-1989			
B16	JP	02150840	A2	Toshihiko et al.	06-11-1990			
B17	JP	02105016	A2	Hideo et al.	04-17-1990			
B18	JP	02108048	A2	Minoru et al.	04-19-1990			
B19	JP	02035450	A2	Toshihiko et al.	07-26-1988			
B20	JP	61020039	A2	Ryosuke	07-06-1984			
B21	WO	00/50425	A1	Boehringer Ingelheim	08-31-2000			
B22	WO	98/34929	A1	Smithkline Beecham	08-13-1998			
B23	WO	98/32439	A1	Smithkline Beecham	07-30-1998			
B24	WO	01/09088	A1	Kirin Beer Kabushiki	02-08-2001			
B25	WO	01/04115	A2	Boehringer Ingelheim	01-18-2001			
B26	WO	2005/048948	A2	Ambit Biosciences	06-02-2005			
B27	WO	02/062763	A2	Bayer Corporation	08-15-2002			
B28	WO	02/083628	A1	Boehringer Ingelheim	10-24-2002			
B29	WO	02/085857	A2	Bayer Corporation	10-31-2002			
B30	WO	02/085859	A1	Bayer Corporation	10-31-2002			
B31	WO	97/09973	A2	Univ. of California	03-20-1997			
B32	WO	02/062763	A2	Bayer Corporation	08-15-2002			
B33	WO	03/068229	A1	Bayer Corporation	08-21-2003			
B34	WO	03/068746	A1	Bayer Corporation	08-21-2003			
B35	WO	03/099771	A2	Novartis AG	12-04-2003			
B36	WO	03/082272	A1	Chiron Corp.	10-09-2003			
B37	WO	02/059102	A2	Aventis Pharma	08-01-2002			

Examiner Signature

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box

OCT 28 2005

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

9

**Complete if Known**

Application Number	10/042,203
Filing Date	January 11, 2002
First Named Inventor	Bernd RIEDL et al.
Group Art Unit	1625
Examiner Name	Rita J. Desai

Attorney Docket Number

BAYER-25A

### FOREIGN PATENT DOCUMENTS (cont'd.)

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
B38	WO	01/07411	A1	Banyu Pharmaceutical	02-01-2001			
B39	UK	1110099		Julia	06-07-1966			
B40	WO	2004078746	A2	Boyer et al.	09-16-2004			
B41	WO	2005037273	A1	Ramurthy et al.	04-28-2005			
B42	WO	2005037285	A1	Ramurthy et al.	04-28-2005			
B43	WO	2005049603	A1	Finsinger et al.	06-02-2005			
B44	WO	2005019192	A1	Hoelzemann et al.	03-03-2005			
B45	WO	2004043374	A2	Anderson et al.	05-27-2004			
B46	WO	2005048948	A2	Milanov et al.	06-02-2005			
B47	WO	2005042520	A1	Staehle et al.	05-12-2005			
B48	WO	2005037829	A1	Staehle et al.	04-28-2005			
B49	WO	2005004864	A1	Buchstaller et al.	01-20-2005			
B50	WO	2004037789	A2	Buchstaller et al.	05-06-2004			
B51	WO	2005047283	A1	Hoelzemann et al.	05-26-2005			
B52	WO	2005002673	A1	Gill et al.	01-13-2005			
B53	WO	02059081	A2	Hocker et al.	08-01-2002			
B54	WO	2005004863	A1	Buchstaller et al.	01-20-2005			
B55	WO	2005032548	A1	Amiri et al.	04-14-2005			
B56	WO	2004085425	A1	Dipietro et al.	10-07-204			
B57	WO	02059102	A2	Deprez et al.	08-01-2002			
B58	WO	0050425	A1	Cirillo et al.	08-31-2000			
B59	WO	0055152	A1	Cirillo et al.	09-21-2000			
B60	WO	0157008	A1	Cusack et al.	08-09-2001			
B61	WO	0107411	A1	Hayama et al.	02-01-2001			
B62	WO	2005058832	A1	Finsinger et al.	06-30-2005			
B63	WO	2005005389	A2	Bruge et al.	01-20-2005			
B64	WO	2004085399	A1	Buchstaller et al.	10-07-2004			
B65	WO	02083642	A1	Breitfelder et al.	10-24-2002			
B66	WO	0071532	A1	Gant et al.	11-30-2000			
B67	WO	0210141	A1	Ahliganian et al.	02-07-2002			

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box

OCT 28 2005

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**Complete if Known**

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

9

Application Number	10/042,203
Filing Date	January 11, 2002
First Named Inventor	Bernd RIEDL et al.
Group Art Unit	1625
Examiner Name	Rita J. Desai

Attorney Docket Number

BAYER-25A

### FOREIGN PATENT DOCUMENTS (cont'd.)

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	<b>B68</b>	WO	9962890	A1	Larson et al.	12-09-1999		
	<b>B69</b>	WO	0109088	A1	Padia et al.	02-08-2001		
	<b>B70</b>	WO	0214281	A1	Cochran et al.	02-21-2002		
	<b>B71</b>	WO	02083628	A1	Cirillo et al.	10-24-2002		
	<b>B72</b>	WO	2004019941	A1	Buchstaller et al.	03-11-2004		
	<b>B73</b>	WO	0035454	A1	Ko et al.	06-22-2000		
	<b>B74</b>	WO	0104115	A2	Zhang et al.	01-18-2001		
	<b>B75</b>	WO	0218346	A1	Cooper et al.	03-07-2002		
	<b>B76</b>	WO	0026203	A1	Pevarello et al.	05-11-2000		
	<b>B77</b>	WO	0043366	A1	Kirin et al.	07-27-2000		
	<b>B78</b>	WO	0056331	A1	Stamos et al.	09-28-2000		
	<b>B79</b>	WO	9820868	A1	Tracey et al.	05-22-1998		
	<b>B80</b>	WO	9203413	A1	Lythgoe et al.	03-05-1992		
	<b>B81</b>	WO	03047523	A2	Lyons et al.	06-12-2003		
	<b>B82</b>	WO	03068228	A1	Dumas et al.	08-21-2003		
	<b>B83</b>	EP	1256587	A1	Omura et al.	11-13-2002		
	<b>B84</b>	EP	1199306	A1	Hayama et al.	04-24-2002		
	<b>B85</b>	EP	0709225	B1	Minami et al.	08-05-1998		

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	<b>C1</b>	Nickel et al., "Carboxylic acid analogues of suramin, potential filaricides," <i>Indian Journal of Chemistry</i> , Vol. 30B, February 1991, p. 182-187	
	<b>C2</b>	Duan et al., "The ins and outs of Raf kinases," <i>TIBS</i> 19, November 1994, p. 474-480.	
	<b>C3</b>	Campbell et al., "Increasing complexity of Ras signaling," <i>Oncogene</i> , (1998) 17, 1395-1413	
	<b>C4</b>	Bolton et al., "Ras oncogene directed approaches in cancer chemotherapy," <i>Annual Reports in Medicinal Chemistry</i> , 29, pp. 165-174	
	<b>C5</b>	Moelling et al., "Signal transduction as target of gene therapy," Institute of Medical Virology, University of Zürich, <i>Recent Results in Cancer Research</i> , Vol. 142, pp. 63-71	


Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**Complete if Known**

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

9

Application Number	10/042,203
Filing Date	January 11, 2002
First Named Inventor	Bernd RIEDL et al.
Group Art Unit	1625
Examiner Name	Rita J. Desai

Attorney Docket Number

BAYER-25A

### NON PATENT LITERATURE DOCUMENTS (cont'd.)

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C6	Internal Medicine, 4 <sup>th</sup> Edition, 1994, pp. 699-715	
	C7	Johannes L. Bos, "Ras oncogenes in human cancer: a review," <i>Cancer Research</i> , 49, 4682-4689, September 1, 1989	
	C8	Kempter et al., "Synthese potentieller Pflanzenschutz- und Schädlingsbekämpfungsmittel aus substituierten Anilinen," Pädagogische Hochschule, Eingegangen am 1.7.1982, 101-120	
	C9	Lyons et al., "Discovery of a novel Raf kinase inhibitor," <i>Endocrine-Related Cancer</i> , (2001) 8, 219-225	
	C10	Lowinger et al., "Design and discovery of small molecules targeting Raf-1 kinase," <i>Current Pharmaceutical Design</i> , 2002, 8, 2269-2278	
	C11	Dumas et al., "Recent developments in the discovery of protein kinase inhibitors from the urea class," <i>Current Opinion in Drug Discovery &amp; Development</i> , 2004, 7(5):600-616	
	C12	Dumas, "Protein kinase inhibitors from the urea class," <i>Current Opinion in Drug Discovery &amp; Development</i> , 2002, 5(5):718-727	
	C13	Lowinger et al., "Discovery of novel class of potent Raf kinase inhibitors: structure activity relationships," <i>Clinical Cancer Research</i> , Vol. 6, Nov. 2000, 4533s	
	C14	Hotte et al., "BAY 43-9006: Early Clinical Data in Patients with Advanced Solid Malignancies," <i>Current Pharmaceutical Design</i> , 2002, 8, 2249-2253	
	C15	Lee et al., "BAY-43-9006: Bayer/Onyx," <i>Current Opinion in Investigational Drugs</i> , 2003, 4(6):757-763	
	C16	Sorbara et al., "BAY-43-9006," <i>Drugs of the Future</i> , 2002, 27(12):1141-1147	
	C17	Khire et al., "Omega-carboxypyridyl substituted ureas as raf kinase inhibitors: SAR of the amid substituent," <i>Bioorg. Med. Chem. Lett.</i> , 14 (2004), 783-786	
	C18	Wilhelm et al., "BAY 43-9006 Exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis," <i>Cancer Research</i> , 64, 7099-7109, October 1, 2004	
	C19	Smith, et al., "Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach." <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 11 (2001) 2775-2778	
	C20	Bankston et al., "A sealeable synthesis of BAY 43-9006: a potent raf kinase inhibitor for the treatment of cancer," <i>Organic Process Research &amp; Development</i> , 2002, 6, 777-781	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box

OCT 28 2005

PTO/SB/08A (08-00)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6

of

9

Application Number	10/042,203
Filing Date	January 11, 2002
First Named Inventor	Bernd RIEDL et al.
Group Art Unit	1625
Examiner Name	Rita J. Desai

Attorney Docket Number

BAYER-25A

### NON PATENT LITERATURE DOCUMENTS (cont'd.)

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. <sup>T<sup>2</sup></sup>
	C21	Strumberg et al., "Results of phase I pharmacokinetic and pharmacodynamic studies of the raf kinase inhibitor BAY 43-9006 in patients with solid tumors," <i>International Journal of Clinical Pharmacology and Therapeutics</i> , Vol. 40, No. 12/2002 (580-581)
	C22	Chang et al., "BAY 43-9006 (Sorafenib) inhibitors ectopic (s.c.) and orthotopic growth of a murine model of renal adenocarcinoma (Renca) predominantly through inhibition of tumor angiogenesis," 96 <sup>th</sup> Annual Meeting, April 16-20, 2005, Anaheim/Orange County, CA
	C23	Panka et al., "BAY 43-9006 induces apoptosis in melanoma cell lines," 96 <sup>th</sup> Annual Meeting, April 16-20, 2005, Anaheim/Orange County, CA
	C24	Auclair, et al., "BAY 43-9006 (Sorafenib) is a potent inhibitor of FLT3 tyrosine kinase signaling and proliferation in AML cells," 96 <sup>th</sup> Annual Meeting, April 16-20, 2005, Anaheim/Orange County, CA
	C25	Murphy et al., "BAY 43-9006 controls tumor growth through inhibition of vascular development," 96 <sup>th</sup> Annual Meeting, April 16-20, 2005, Anaheim/Orange County, CA
	C26	Spronsen et al., "Novel treatment strategies in clear-cell metastatic renal cell carcinoma," <i>Anti-Cancer Drugs</i> , 2005, 16:709-717
	C27	Thaimattam et al., "3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies," <i>Bioorganic &amp; Medicinal Chemistry</i> , 12(2004) 6415-6425
	C28	Danson et al., "Improving outcomes in advanced malignant melanoma," <i>Drugs</i> , 2005, 65(6):733-743
	C29	Heim et al., "Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006," <i>International Journal of Clinical Pharmacology and Therapeutics</i> , Vol. 41, No. 12/2003 (616-617)
	C30	Richly et al., "Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer," <i>International Journal of Clinical Pharmacology and Therapeutics</i> , Vol. 42, No. 11/204 (650-651)
	C31	Mross et al., "Drug-drug reaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors," <i>International Journal of Clinical Pharmacology and Therapeutics</i> , Vol. 41, No. 12/2003 (618-619)
	C32	Richly et al., "A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors," <i>International Journal of Clinical Pharmacology and Therapeutics</i> , Vol. 41, No. 12/2003 (620-621)

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box

OCT 28 2005

PATENT & TRADEMARK OFFICE  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

7

of

9

Complete if Known

Application Number	10/042,203
Filing Date	January 11, 2002
First Named Inventor	Bernd RIEDL et al.
Group Art Unit	1625
Examiner Name	Rita J. Desai

Attorney Docket Number

BAYER-25A

### NON PATENT LITERATURE DOCUMENTS (cont'd.)

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C33	DeGrendele, "Activity of the raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors," <i>Clinical Colorectal Cancer</i> , May 2003, pp. 16-18	
	C34	Hubbard, "Oncogenic mutations in B-Raf: some losses yield gains," Skirball Institute of Biomolecular Medicine and Department of Pharmacology, New York University School of Medicine, New York, NY	
	C35	Thompson et al., "Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery," <i>Curr. Opin. Pharmacol.</i> , 2005 Aug., 5(4):350-6	
	C36	Moore et al., "Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors," <i>Annals of Oncology</i> , 16:1688-1694, 2005	
	C37	Ahmad et al., "Kinase inhibition with BAY 43-9006 in renal cell carcinoma," <i>Clinical Cancer Research</i> , Vol. 10, 6388s-6392s, 15 Sept. 2004	
	C38	Wan et al., "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF," <i>Cell</i> , Vol. 116, 855-867, 19 March 2004	
	C39	Hanson, "Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis, Inhibitors of p38 kinase," <i>Exp. Opin. Ther. Patents</i> , (1997) 7(7):729-733	
	C40	Strumberg et al., "Phase I clinical and pharmacokinetic study of the novel raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors," <i>Journal of Clinical Oncology</i> , Vol. 23, No. 5, 10 Feb. 2005, 965-972	
	C41	Regan et al., "Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate," <i>J. Med. Chem.</i> , 2002, 45, 2994-3008	
	C42	Clark et al., "Safety and pharmacokinetics of the dual action raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors," <i>Clin. Cancer Res.</i> , 2005:11(15), 1 August 2005, 5472-5480	
	C43	Wilson et al., "The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase," <i>Chemistry &amp; Biology</i> , 1997, Vol. 4, No. 6, 423-431	
	C44	Hotte et al., "BAY 43-9006: early clinical data in patients with advanced solid malignancies," <i>Current Pharmaceutical Design</i> , 2002, 8, 2249-2253	
	C45	Jeffcoat et al., "The metabolism and toxicity of halogenated carbanilides," <i>Drug Metabolism and Disposition</i> , Vol. 5, No. 2, 157-166	
	C46	Murata et al., "Facile synthesis of new pyrrolo[3,4-d]pyrimidine-2,4-diones," <i>Chem. Pharm. Bull.</i> , 22(5) 1212-1213 (1974)	

Examiner  
Signature

Date  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

Please type a plus sign (+) inside this box



OCT 28 2005

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO

*Complete if Known*

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

8

of

9

Application Number	10/042,203
Filing Date	January 11, 2002
First Named Inventor	Bernd RIEDL et al.
Group Art Unit	1625
Examiner Name	Rita J. Desai

Attorney Docket Number

BAYER-25A

### NON PATENT LITERATURE DOCUMENTS (cont'd.)

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C47	Yasuo et al, "Intra-arterial ACNU, CDDP chemotherapy for brain metastases from lung cancer: comparison of cases with and without intra-arterial mannitol infusion," <i>Neurol. Surg.</i> , (1993) vol. 21, no. 6, pp. 513-518	
	C48	Murata et al., "Facile synthesis of new pyrrolo[3,4-d]pyrimidine-2,4-diones," <i>Chemical &amp; Pharmaceutical Bulletin</i> , (1974), 22(5):1212-13	
	C49	Hanson, "Inhibitors of p38 kinase," <i>Expert Opinion on Therapeutic Patents</i> , July 1997, vol. 7, no. 7, pp. 729-733(5)	
	C50	Garcia-Lopez et al., "New routes for the synthesis of pyrrolo[3,2-d]- and -[2,3-d]pyrimidine systems starting from a common pyrrole derivative," <i>Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry</i> (1972-1999) (1978), (5), 483-7	
	C51	Wilhelm et al., "BAY 43-9006: preclinical data," <i>Curr Pharm Des</i> , 2002, 8(25):2255-7	
	C52	Wright et al., "Clinical trials referral resource. Current clinical trials of BAY 43-9006, Part 1," <i>Oncology</i> , 2005 Apr, 19(4):499-502	
	C53	Dumas, "Protein kinase inhibitors from the ureas class," <i>Current Opinion in Drug Discovery &amp; Development</i> , 2002, Vol. 5, No. 5, 718-727	
	C54	Patent Abstracts of Japan, Publication No. 02-023337, published 01-28-1990	
	C55	Patent Abstracts of Japan, Publication No. 02-022650, published 01-25-1990	
	C56	Wisner et al., "Analogues of platelet activating factor. 7. Bis-aryl amide and bis-aryl urea receptor antagonists of PAF," <i>J. Med. Chem.</i> , 1992, 35, 4779-4789	
	C57	Ravi et al., "Activated raf-1 causes growth arrest in human small cell lung cancer cells," <i>J. Clin. Invest.</i> , pp. 153-159	
	C58	Lemoine, "Overview of ras oncogenes and their clinical potential," Chapter 10,	
	C59	<i>Drug, facts and comparisons</i> , 1994 Edition, pp. 2703-2705	
	C60	Siu et all, "Phase I study of oral raf-1 kinase inhibitor BAY 43-9006 with gemcitabine in patients with advanced solid tumors," <i>Proc Am Soc Clinic Oncol</i> , 22:207, 2003 (abstr 828)	
	C61	Escudier et al., "Randomized phase III trial of the raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)," Meeting: 2005 ASCO Annual Meeting, Category: Genitourinary Cancer, Subcategory: Kidney Cancer, Abstract No. 4510	
	C62	Eisen et al., "Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients," Meeting: 2005 ASCO Annual Meeting, Category: Melanoma, Subcategory: Melanoma, Abstract No. 7508	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.

+ + + + +

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

9

of

9

Application Number	10/042,203
Filing Date	January 11, 2002
First Named Inventor	Bernd RIEDL et al.
Group Art Unit	1625
Examiner Name	Rita J. Desai

Attorney Docket Number

BAYER-25A

### NON PATENT LITERATURE DOCUMENTS (cont'd.)

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C63	Adjei et al., "A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC)," Meeting: 2005 ASCO Annual Meeting, Category: Developmental Therapeutics: Molecular Therapeutics, Subcategory: Antiangiogenic or Antimetastatic agents, Abstract No. 4510	
	C64	Carling et al., "1-(3-cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1,3-dihydroimidazol-2-one: A selective high-affinity antagonist for the human dopamine D <sub>4</sub> receptor with excellent selectivity over ion channels," <i>J. Med. Chem.</i> , 1999, 42, 2706-2715	
	C65	Van Muijlwijk-Koezen et al., "Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A <sub>3</sub> receptor," <i>J. Med. Chem.</i> , 2000, 43, 2227-2238	
	C66	Eisenhauer et al., "Impact of new non-cytotoxics in the treatment in ovarian cancer," <i>Int. J. Gynecol Cancer</i> , 2001, 11 (Suppl. 1), 68-72	
	C67	Kubo et al., "Synthesis and structure-activity relationship of quinazoline-urea derivatives as novel orally active VEGF receptor tyrosine kinase selective inhibitors," #913, XP-001152608	
	C68	Carter et al, "Anti-tumor efficacy of the orally active raf kinase inhibitor BAY 43-9006 in human tumor xenograft models," #4954, XP-001145482	
	C69	Strumberg et al., "Phase I and pharmacokinetic study of the raf kinase inhibitor bay 43-9006 in patients with locally advanced or metastatic cancer," #2921, XP-001145481	
	C70	Dumas et al., "1-phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 10 (2000), 2051-2054	
	C71	Riedl et al., "Potent raf kinase inhibitors from the diphenylurea class: structure activity relationships," #4956, XP-001145518	
	C72	Iwadate et al., "Intra-arterial ACNU, CDDP chemotherapy for brain metastases from lung cancer: comparison of cases with and without intra-arterial mannitol infusion," Dept of Neurological Surgery, Chiba Cancer Center Hospital, Clinical Trial, Journal Article, Randomized Controlled Trial, Vol. 21, No. 6, 513-518	
	C73	Geiger et al., "Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice," <i>Clinical Cancer Research</i> , Vol. 3, 1179-1185, July 1997	
	C74	Cunningham et al., "A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma," <i>Cancer</i> , September 2001, Vol. 92, No. 5, 1265-1271	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.